GTX-102 medium dose slow Period 1 and Period 2 ( DrugBank: GTX-102 )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
65原発性免疫不全症候群1

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05531890
(ClinicalTrials.gov)
September 13, 202231/8/2022Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy SubjectsCrossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection and an Oral Solution of Betamethasone in Healthy SubjectsAtaxia TelangiectasiaDrug: GTX-102 medium dose fast Period 1 and Period 2;Drug: GTX-102 medium dose slow Period 1 and Period 2;Drug: GTX-102 high dose fast Period 1 and Period 2;Drug: GTX-102 low dose fast Period 1 and Period 2;Drug: Betamethasone solution as intramuscular injection Period 1 and Period 2;Drug: Betamethasone Oral Solution Period 1 and Period 2Acasti Pharma Inc.NULLActive, not recruiting18 Years55 YearsAll48Phase 1Canada